Lobbying Information
Subject Matters
- Economic Development
- Health
- Industry
- Intellectual Property
- Internal Trade
- Science and Technology
- Taxation and Finance
Subject Matter Details
Policies or Program
- Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with the Canadian Agency for Drugs and Technologies in Health (CADTH) and/or other pan-Canadian health organizations.
- Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
- Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada, including the Biomanufacturing and Life Sciences Strategy.
- Policies related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
- The federal role in considering developing and/or funding a national pharmacare program, including engagement with the Advisory Council on the Implementation of National Pharmacare and its Secretariat on issues related to access to medicines and rare disease and orphan drug policies, including the evolving Drugs for Rare Diseases Strategy.
Policies or Program, Regulation
- Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
Communication Techniques
-
Written communication
-
Oral communication
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Government Institutions
-
Finance Canada (FIN)
-
Health Canada (HC)
-
House of Commons
-
Innovation, Science and Economic Development Canada (ISED)
-
Patented Medicine Prices Review Board (PMPRB)
-
Prime Minister's Office (PMO)
-
Privy Council Office (PCO)
-
Senate of Canada
Client Details
Government funding
No government funding was received during the last completed financial year.
Client Contact Information
Address:
3100 Rutherford Road Suite 300
Vaughan, ON L4K 0G6
Canada
Telephone number:
866-393-1188
Web address:
https://alexion.com/worldwide/canada
Client representative
Kathleen Whelan, Country Lead, International Government Affairs & Policy
Parent Company Information
- AstraZeneca / AstraZeneca
-
1004 Middlegate Road, Suite 5000
Mississauga, ON L4Y 1M4
Canada
Coalition Members Information
Alexion Pharma Canada Corp. is not a coalition.
Individual, organization or corporation with a Direct Interest Beneficiary Information
The activities of Alexion Pharma Canada Corp. are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Alexion Pharma Canada Corp. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
Lobbyist Details
Philip Delistoyanov
|
No public offices held
Business address:
130 Albert Street, Suite 408
Ottawa, ON K1P 5G4
Canada
Telephone number:
613-864-2934
Consultant Firm and Address
Firm:
3Sixty Public Affairs
Address:
150 Metcalfe Street, Suite 604
Ottawa, ON K2P 1P1
Canada
Telephone number:
613-864-2934
